Redeye comments on the outcome of Initiator Pharma’s recent rights issue. While the subscription level was below the initial target, the rights issue still secures sufficient proceeds to fund key priorities, including the planned phase IIa vulvodynia trial and further business development. We argue that the coming period will be important for re-establishing investor confidence through clinical progress and renewed momentum.
LÄS MER
